
AtriCure (ATRC) Stock Forecast & Price Target
AtriCure (ATRC) Analyst Ratings
Bulls say
AtriCure Inc has demonstrated robust financial growth, with pain management revenue reaching $22.6 million, reflecting a year-over-year increase of 27.3%, and Appendage Management revenue of $45.5 million, up 12.8% year-over-year. The company's total revenue for the fourth quarter of 2025 was reported at $140.5 million, marking a 13.1% increase year-over-year and indicating strong performance across its global operations. Furthermore, potential upside drivers include anticipated stronger sales from new product launches and improving margins, which may enhance profitability and free cash flow in the future.
Bears say
AtriCure Inc's recent financial performance indicates challenges in key revenue segments, particularly a significant decline in its Minimally Invasive Ablation product line, with revenue dropping by 24.3% year-over-year, suggesting ongoing struggles with market acceptance. Additionally, the growth rate for US Appendage Management has notably decreased, falling from 21.7% in the previous quarter to 11.0% in the current quarter, raising concerns about the sustainability of future revenue growth. Furthermore, the risks outlined include potential market share loss to new competitors, slower margin improvement, and the impact of rising healthcare costs, which could hamper overall financial stability and profitability.
This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.
AtriCure (ATRC) Analyst Forecast & Price Prediction
Start investing in AtriCure (ATRC)
Order type
Buy in
Order amount
Est. shares
0 shares